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Background & Aims: Chondroitin-glucuronate C5-epimerase is an enzyme that 
converts D-glucuronic acid to L-iduronic acid residues in dermatan sulfate biosynthesis. 
It is also identified to be a tumor-associated antigen recognized by cytotoxic T cells 
(CTLs) and its enhanced expression in many cancers has been reported. In the present 
study, we investigated the usefulness of this molecule as an immunotherapeutic target in 
hepatocellular carcinoma (HCC).  
Methods: The expression of chondroitin-glucuronate C5-epimerase in hepatoma cell 
lines and HCC tissues was confirmed by immunofluorescence and 
immunohistochemical analysis. CTL responses were investigated by several 
immunological techniques using peripheral blood mononuclear cells (PBMCs) or 
tumor-infiltrating lymphocytes. To determine the safety of immunotherapy using 
chondroitin-glucuronate C5-epimerase-derived peptide, 12 patients with HCC were 
administered s.c. vaccinations of the peptides and analyzed. 
Results: Chondroitin-glucuronate C5-epimerase was expressed in HCC cell lines and 
human tissues including alpha-fetoprotein (AFP)-negative individuals. 
Chondroitin-glucuronate C5-epimerase-specific CTLs could be generated by 
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stimulating PBMCs of HCC patients with peptides and they showed cytotoxicity against 
HCC cells expressing the protein. The frequency of CTL precursors investigated by 
enzyme-linked immunospot (ELISPOT) assay was 0-34 cells/3X105 PBMCs and the 
infiltration of interferon-gamma-producing CTLs into the tumor site was confirmed. In 
the vaccination study, no severe adverse events were observed and the peptide-specific 
CTLs were induced in 4 of 12 patients tested. 
Conclusions: Chondroitin-glucuronate C5-epimerase is a potential candidate for tumor 
antigen with immunogenicity and the peptides derived from this antigen could be useful 
in HCC immunotherapy. 
 
Electronic word count: 238 words 








Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver 
and has gained much clinical interest because of its increasing incidence (1). It is 
treatable by hepatectomy or percutaneous ablation when the lesion is localized to some 
extent, and radical therapeutic effects can be obtained when resection or cauterization 
with a safety margin can be performed (2). However, the recurrence rate is very high (3), 
because active hepatitis and cirrhosis in surrounding non-tumor liver tissues have the 
potential to generate HCC de novo.   
To protect against recurrence, tumor antigen-specific immunotherapy is an attractive 
option. Many tumor-associated antigens and their epitopes recognized by cytotoxic T 
cells (CTLs) have been identified during the last two decades. However, only a few 
HCC-specific tumor antigens and their antigenic epitopes have been used for human 
trials (4, 5).  
Chondroitin-glucuronate C5-epimerase is an enzyme that converts D-glucuronic acid 
to L-iduronic acid residues in dermatan sulfate biosynthesis and identical to squamous 
cell carcinoma antigen recognized by T cells 2 (SART2) (6). It is expressed in many 
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malignant tumor cell lines and various histological types of cancer tissues and function 
as tumor rejection antigens (7). In addition, peptides containing chondroitin-glucuronate 
C5-epimerase epitopes are capable of generating CTLs, and therefore, have been used 
for immunotherapy to treat several kinds of cancers (8, 9). These reports suggest 
chondroitin-glucuronate C5-epimerase to be useful as a target antigen in HCC 
immunotherapy. Furthermore, in previous study, we compared T cell immune responses 
against the various tumor-associated antigen (TAA)-derived peptides (10). The results 
of the study showed that CTLs of HCC patients were frequently responsive against a 
single chondroitin-glucuronate C5-epimerase-derived peptide. Regarding tumor 
immunotherapy, it has recently been reported that strong immune responses can be 
induced at an earlier post-vaccination time using, as peptide vaccines, epitopes that 
frequently occur in peripheral blood CTL precursors (11). These results also suggest that 
chondroitin-glucuronate C5-epimerase is useful as a target for HCC immunotherapy. 
In the present study, we examined chondroitin-glucuronate C5-epimerase expression 
in various hepatoma cell lines and HCC tissues of patients, and analyzed immune 
responses to the antigen using peripheral blood mononuclear cells (PBMCs) and 
tumor-infiltrating lymphocytes (TILs). Furthermore, to investigate the usefulness of 
HCC immunotherapy targeting chondroitin-glucuronate C5-epimerase, we analyzed the 
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safety and cellular immune responses in the patients vaccinated with 
chondroitin-glucuronate C5-epimerase-derived peptide. 
 
MATERIALS AND METHODS 
 
Patients 
Forty-four HLA-A24-positive HCC patients were examined for the expression of 
chondroitin-glucuronate C5-epimerase and cellular immune responses. Twelve HCC 
patients were enrolled in vaccination study. Informed consent was obtained from each 
patient included in the present study and the study protocol conformed to the ethical 
guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the 
regional ethics committee.  
The diagnosis of HCC was histologically confirmed by taking US-guided needle 
biopsy specimens in 17 cases, surgical resection in 9 cases, and autopsy in 5 cases. For 
the remaining 13 patients, the diagnosis was based on typical hypervascular tumor 
staining on angiography in addition to typical findings, which showed hyperattenuated 
areas in the early phase and hypoattenuation in the late phase on dynamic CT (12). The 
pathological grading of tumor cell differentiation was assessed according to the general 
7 
 
rules for the clinical and pathologic study of primary liver cancer (13). The severity of 
liver disease was evaluated according to the criteria of Desmet et al. using biopsy 
specimens of liver tissue (14). Eleven normal blood donors and 23 chronic hepatitis C 
patients (11 liver cirrhosis) with HLA-A24, who were diagnosed by liver biopsy, served 
as controls.  
 
Cell lines 
Four human hepatoma cell lines (HLF, Hep3B, HLE and Huh7) and Paca-2, which is 
a pancreatic cancer cell line, were cultured in DMEM (Gibco, Grand Island, NY) with 
10% fetal calf serum (FCS) (Gibco). The HLA-A*2402 gene-transfected C1R cell line 
(C1R-A24) was cultured in RPMI 1640 medium containing 10% FCS and 500 g/ml of 
hygromycin B (Sigma, St Louis, MO), and K562 was cultured in RPMI 1640 medium 
containing 10% FCS (15).  
 
Immunofluorescence and immunohistochemical analysis 
The expression of chondroitin-glucuronate C5-epimerase was examined in 4 different 
Hepatoma cell lines. A pancreatic cancer cell line (Paca 2) was used as a positive control. 
They were fixed in acetone with methanol for 5 min and incubated with rabbit 
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anti-human chondroitin-glucuronate C5-epimerase (ProteinTech Group, Inc, Chicago, 
IL; diluted 1:50) or mouse anti-human AFP (Nichirei Bioscience, Tokyo, Japan) 
antibody overnight at 4°C. For immunofluorescence analyses, Alexa Fluor 
488-conjugated anti-rabbit and anti-mouse IgG (Invitrogen, Tokyo, Japan) were used 
for chondroitin-glucuronate C5-epimerase and AFP detection, respectively. 
The expression in HCC tissue was examined in 26 patients. Non cancerous tissues 
were also obtained by a paired liver biopsy or surgical resection from the non neoplastic 
liver tissue. The tissues were fixed in buffered zinc formalin (Anatech Ltd, Battle Creek, 
MI), embedded in paraffin, sectioned (at 3 m), and stained with hematoxylin and eosin. 
The sections were deparaffinized, treated in a pressure cooker for 1–4 min, and 
incubated with rabbit anti-human chondroitin-glucuronate C5-epimerase or AFP 
(DakoCytomation, Inc, Carpinteria, CA) antibody overnight at 4°C. The tissue sections 
were visualized using the DAKO EnVisionTM+ System (DakoCytomation, Inc, 
Carpinteria, CA). The expression levels were semi-quantitatively classified into four 
categories (negative to low, moderate and high; negative: no staining, low: <20% of the 





PBMCs and TILs were isolated as described previously (16). ELISPOT assays were 
performed as reported previously with the following modifications (16). Three different 
peptides (Peptide 1; DYSARWNEI, Peptide 2; AYDFLYNYL, Peptide 3; SYTRLFLIL) 
derived from chondroitin-glucuronate C5-epimerase were used for the detection of 
CTLs. Negative controls consisted of a HIV envelope-derived peptide (HIVenv584) (17). 
Positive controls consisted of 10 ng/ml of phorbol 12-myristate 13-acetate (PMA, 
Sigma) or a CMV pp65-derived peptide (CMVpp65328) (18). The peptides were 
synthesized at Sumitomo Pharmaceuticals (Osaka, Japan). The colored spots were 
counted with a KS ELISpot Reader (Zeiss, Tokyo, Japan). The number of specific spots 
was determined by subtracting the number of spots in the absence of an antigen from 
the number in its presence. Responses to peptides derived form chondroitin-glucuronate 
C5-epimerase in HCC patients were considered positive if the number of specific spots 
was more than the mean + 3SD of that in normal donors and if the number of spots in 
the presence of an antigen was at least twofold greater than the number in its absence. 
Responses to peptides HIVenv584 and CMVpp65328 were considered positive if more 
than 10 specific spots were detected and if the number of spots in the presence of an 
antigen was at least twofold that in its absence. ELISPOT assays were also performed in 
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12 patients whose PBMCs were available for analysis at 2-4 weeks after RFA. 
 
CTL induction and Cytotoxicity assay 
Peptide 3 (SYTRLFLIL), which correspond to HLA-A24 restricted CTL epitope (7, 
19), was used to produce chondroitin-glucuronate C5-epimerase-specific T cells. 
CTLs were expanded from PBMCs as detailed previously (16). C1R-A24 cells and 
human hepatoma cell lines were used as targets. Cytotoxicity assay was performed by 
chromium-release assay. Percent cytotoxicity was calculated as previously described 
(16). For the assay using hepatoma cell lines, cytotoxicity was considered positive when 
it was higher than that of CTLs against K562 which show non-specific lysis.  
 
Vaccination study 
Twelve HLA-A24-positive HCC patients who were treated by radiofrequency 
ablation (RFA) and obtained complete necrosis of tumor with safety margin were 
enrolled in this vaccine study (Trial registration: UMIN000004540). They were 
vaccinated with peptide 3 (SYTRLFLIL) into the subcutaneous tissue of the armpit 4 
weeks after RFA. The peptide utilized in the present study was prepared under 
conditions of Good Manufacturing Practice (NeoMPS, San Diego, CA). One milliliter 
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of the peptide, which was supplied in vials containing 0.04-4mg/ml sterile solution, was 
mixed with an equal volume of incomplete Freund’s adjuvant (Montanide ISA-51; 
Seppic, Paris, France) and emulsified in 5-ml syringes. 1.5 ml of the preparing peptide 
was injected and the patients received three biweekly vaccinations. Toxicity was 
assessed every 2 weeks using the National Cancer Institute’s Common Toxicity Criteria. 
To evaluate the immunological effect, ELISPOT assay was performed before and 4 
weeks after the final vaccination. Responses to vaccination were considered positive if 
more than 10 specific spots were detected and if the number of spots after vaccination 
was at least twofold that before vaccination. After final vaccination, HCC recurrence 
was evaluated by dynamic CT or MRI every 3 months. 
 
Statistical analysis 
Data are expressed as the mean ± SD. The Mann-Whitney’s U test was used for 
statistical analyses of chondroitin-glucuronate C5-epimerase expression in HCC and 
non-cancerous liver tissues. The x2 test with Yates’ correction and the unpaired t-test 
were used for univariate analysis of the effect of variables on the T cell response against 






Expression of chondroitin-glucuronate C5-epimerase in hepatoma cell lines and 
HCC tissues  
Chondroitin-glucuronate C5-epimerase was expressed in all hepatoma cells (Fig. 1A) 
and its cellular distribution was cytoplasmic, similar to that in Paca-2, a pancreatic 
cancer cell line reported to express the protein (7). The expression was observed even in 
the hepatoma cell lines not expressing AFP, namely HLF and HLE.  
The expression of chondroitin-glucuronate C5-epimerase in HCC tissues was 
examined in 26 HCC patients. A representative result for one HCC patient is shown in 
Fig. 1B. In this case, the expression of chondroitin-glucuronate C5-epimerase was 
observed in HCC tissue but not in non-cancerous areas. In addition, AFP was not 
detected in HCC tissue. To compare the expression levels of this protein between 
cancerous and non-cancerous tissues, the expression was semi-quantitatively classified 
into four categories as described in materials and methods, and analyzed. The 
expression levels were higher in HCC tissue than in the non-cancerous tissue (p < 
0.0001) (Fig. 1C). The expression in liver tissue was also observed in the patients with 
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chronic hepatitis and liver cirrhosis (Control), however, the expression levels were 
lower than those in HCC tissue (p=0.0137). The expression of chondroitin-glucuronate 
C5-epimerase and AFP in HCC tissue was observed in 26 (100%) and 12 (46%) of 26 
patients, respectively (Fig. 1D). The expression of chondroitin-glucuronate 
C5-epimerase was observed even in the HCC tissues without AFP expression. 
 
Detection of chondroitin-glucuronate C5-epimerase-specific T cells by IFN- 
ELISPOT analysis 
The clinical profiles of the 11 healthy normal donors, 12 patients with chronic 
hepatitis C, 11 patients with liver cirrhosis and 44 patients with HCC analyzed in the 
present study are shown in Table 1. 
To determine whether a significant number of T cells specifically reacted with the 
chondroitin-glucuronate C5-epimerase-derived peptides (peptide 1, 2 and 3) in HCC 
patients, ELISPOT assays were performed using PBMCs from 11 healthy donors (Fig. 
2A). The number of specific spots was 1.0±1.3, 1.5±1.3 and 1.0±1.4/3X105 PBMCs, 
respectively. Similarly, cells that specifically reacted with the peptides were counted 
among chronic hepatitis C and liver cirrhosis patient-derived PBMCs. Regarding a 
value larger than the mean + 3SD of the number of T cells that specifically reacted with 
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the peptide in healthy donor-derived PBMCs as a significant response, 1 of 23 (4.3%) 
patients showed a significant response to each of the chondroitin-glucuronate 
C5-epimerase-derived peptides (Fig. 2A). 
In the same analysis of HCC patients, 10.8, 16.2 and 27.0% of the patients showed 
significant responses to peptide 1, 2 and 3, respectively (Fig. 2B). A significant 
response specific to CMVpp65328 was detected in 36.4%, 34.8% and 45.9% of healthy 
donors, disease control groups and HCC patients, respectively, with no significant 
difference among the three groups. On the other hand, no significant response to 
HIVenv584 was observed in all groups. 
To clarify the clinical characteristics of chondroitin-glucuronate 
C5-epimerase-specific T cell responses in HCC patients, the clinical background was 
compared between patients who showed positive responses to chondroitin-glucuronate 
C5-epimerase-derived peptides and those who did not. The clinical features of both 
groups were not statistically different in terms of age, sex, serum AFP levels, 
differentiation of HCC, tumor multiplicity, vascular invasion, TNM factors and stages, 
histology of the non-tumor liver, liver function and the type of viral infection (Table 2). 
Chondroitin-glucuronate C5-epimerase-specific T cells had been generated even in the 
early stages of HCC. 
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Next, to examine the existence of chondroitin-glucuronate C5-epimerase-specific T 
cells among TILs, we performed a similar analysis in another 7 patients from whom 
samples of both PBMCs and TILs could be obtained. In the assay using PBMCs and 
TILs, 4 of 7 (57.1%) and 5 of 7 (71.4%) patients, respectively, showed significant 
responses to chondroitin-glucuronate C5-epimerase-derived peptide (peptide 3) (Fig. 
3A). A positive T cell response in TILs was observed even in one patient without a 
positive T cell response in PBMCs (patient 39). 
 
Cytotoxic activity of chondroitin-glucuronate C5-epimerase-specific CTLs against 
hepatoma cell lines 
Whether the chondroitin-glucuronate C5-epimerase-derived peptides used were 
capable of generating peptide-specific CTLs from PBMCs was investigated in 18 HCC 
patients. The CTLs specific to chondroitin-glucuronate C5-epimerase could be induced 
in 8 of 18 (44.4%) patients (Fig.3B and C). They exhibited cytotoxicity against 
hepatoma cell lines with the HLA-A24 molecule and expression of 
chondroitin-glucuronate C5-epimerase, which correspond to HLF and HLE, but not 




Clinical safety of chondroitin-glucuronate C5-epimerase-derived peptide and its 
immunological effects 
The clinical profiles of the 12 HCC patients with vaccination are shown in Table 3. 
The treatment was well-tolerated and there were no treatment-related serious adverse 
events. The most common adverse event was grade 1 injection-site reaction manifesting 
as pain, pruritus, skin induration and rubor. The worsening of hepatitis or liver function 
was not observed in any of the vaccinated patients.  
 In the analysis of ELISPOT assay using PBMCs of patients with vaccination, 4 
patients demonstrated an immune response with increasing IFN- producing T cells 
responded with the corresponding peptide in PBMCs after vaccination (Fig. 4A and 
Table 3). All of the patients that responded were immunized with 3.0 mg of peptide. 
None of the patients immunized with 0.03 or 0.3 mg of peptide showed an enhancement 
of peptide-specific immune response. The enhancement of immunological response to 
HIVenv584 and CMVpp65328 was not observed in any patients except patient A2. 
To examine whether similar occurs for the immune response in HCC patients with 
only RFA, we analyzed chondroitin-glucuronate C5-epimerase-derived peptide-specific 
T cell responses in 12 HCC patients without vaccination, whose PBMCs were available 
for analysis at 2-4 weeks after RFA. In this analysis, we observed an increase of the 
17 
 
frequency of chondroitin-glucuronate C5-epimerase-derived peptide-specific T cells in 
2 of 12 patients (Fig. 4B). The frequency of the patients who showed an increase in the 
number of chondroitin-glucuronate C5-epimerase-derived peptide-specific T cells was 
higher in the patients with vaccination of 3 mg of peptide (66.7%) than in those without 
vaccination (16.7%). 
Finally, we examined the HCC recurrence rate after RFA between the patients with 
and without the peptide-specific CTL response to examine the clinical effect of an 
increase of chondroitin-glucuronate C5-epimerase-derived peptide-specific CTLs after 
vaccination. In the analysis, the recurrence rate in the patients with an increase of the 
peptide-specific CTLs after vaccination (2 of 4 patients, 50%) was lower than that in the 
patients without immune response (6 of 8 patients, 75%) at 300 days after RFA, 






Many tumor-associated antigens and their epitopes capable of inducing HLA-class 
I-restricted CTLs have been identified in various cancers. Some of the epitopes have 
been under investigation for the treatment of cancer, with major clinical responses in 
some trials (11, 20-22).  
With regard to immunotherapy for HCC, AFP is considered a useful 
tumor-associated antigen and AFP-derived peptides have actually been used in clinical 
trials (5, 23-25). However, in general, the production of AFP depends on the size of the 
tumor, with AFP expressed in only 0-40% of HCCs less than 30mm in size (26). 
Therefore, for immunotherapy for HCC in cases where AFP is not expressed in tumor 
tissue, it is necessary to identify other tumor-associated antigens.  
In the present study, the expression of chondroitin-glucuronate C5-epimerase was 
observed in all of the HCC tissues examined and independent of differential degree, size, 
TNM stage and the expression of AFP in the tumor. These results suggest the advantage 
of these antigens as a target for immunotherapy of HCC.  
On the other hand, the expression of this protein was also observed in non-cancerous 
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tissue of HCC patients, although less frequently and at lower levels than in HCC tissue. 
Our results are consistent with the recent finding that chondroitin-glucuronate 
C5-epimerase is expressed in some normal tissues including liver tissue (6). Such 
results imply that immunotherapy targeting chondroitin-glucuronate C5-epimerase may 
have adverse effects on liver tissue expressing the protein. Therefore, we next examined 
the existence and specificity of chondroitin-glucuronate C5-epimerase-specific CTLs in 
HCC patients. 
The presence of chondroitin-glucuronate C5-epimerase-recognizing CTLs has been 
reported as SART2-specific CTLs in lung, gastric and pancreatic cancer patients (7, 27, 
28). However, to our knowledge, there has been no report of the presence of 
chondroitin-glucuronate C5-epimerase-specific CTLs in HCC patients except our recent 
study using only one SART2-derived peptide (10). In this study, we used 3 different 
HLA-A24 restricted peptides which were previously identified and derived from 
naturally processed squamous cell carcinoma antigen. The HLA-A24 allele is found in 
60% of Japanese (29), and therefore, to use HLA-A24 restricted peptides has the 
advantage of analyzing CTL responses to tumor associated antigens in Japanese 
patients. 
We showed that chondroitin-glucuronate C5-epimerase-specific CTLs could be 
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generated by stimulating PBMCs with peptides, and the CTLs were cytotoxic to 
hepatoma cell lines. Chondroitin-glucuronate C5-epimerase-specific immune responses 
were observed frequently only in HCC patients and the frequency of CTLs was higher 
in HCC patients than control groups, indicating that the immune responses are specific 
to HCC. Furthermore, the CTLs were also detected among TILs, suggesting that they 
infiltrate the tumor. Based on these findings, we confirmed that chondroitin-glucuronate 
C5-epimerase-specific CTL precursors exist in HCC patients and the immune responses 
are specific for HCC. 
In previous study, we reported that the frequency of TAA-derived peptide-specific 
CTLs in HCC patients was 0-92 cells/3X105 PBMCs and the frequency of the patients 
who showed immune responses to each peptide was 0-19% (10). In the present study, 
the frequency of chondroitin-glucuronate C5-epimerase-derived peptide-specific CTLs 
in HCC patients was 0-30 cells/3X105 PBMCs and the frequency of the patients who 
showed immune responses to the peptides was 11-27%. These results show that the 
frequencies of chondroitin-glucuronate C5-epimerase-specific CTLs in PBMCs and the 
patients with CTLs responsive to the TAA are very similar to those of previously 
identified immunogenic TAA-derived epitopes and suggest that the antigen and its CTL 
epitope are immunogenic. In addition, the CTLs were generated even in the early stages 
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of HCC. These results suggest the advantages of using chondroitin-glucuronate 
C5-epimerase-derived peptides as a vaccine for immunotherapy of HCC. 
For the next step to investigate the usefulness of chondroitin-glucuronate 
C5-epimerase as an immunotherapeutic target in HCC, we examined the safety and 
efficacy of chondroitin-glucuronate C5-epimerase-derived peptide as a cancer vaccine. 
In previous studies using chondroitin-glucuronate C5-epimerase-derived peptides for 
several cancers, they were reported to be safe. However, most patients with HCC have 
chronic liver disease. Therefore, safety of the peptide vaccine should be confirmed in 
the patients with chronic hepatitis or cirrhosis. The present vaccination study included 9 
patients with chronic liver diseases (4 chronic hepatitis and 5 cirrhotic patients) 
confirmed by histological examination and there was no severe adverse event in all 
patients vaccinated. The induction of chondroitin-glucuronate C5-epimerase-specific 
CTLs was observed in 4 of 6 (66.7%) patients vaccinated with 3mg of peptide, which is 
similar to the frequency of responded patients reported in other peptide vaccination 
studies (11, 20).  
Apart from induction of CTLs, the efficacy of chondroitin-glucuronate 
C5-epimerase-derived peptides as a vaccine for advanced HCC is still unclear. In 
previous vaccine studies for advanced HCC, AFP, hTERT, and glypican-3 have been 
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targeted as tumor-associated antigens for the treatment (25, 30-32). In these studies, 
peptide-specific CTLs were reported to be induced in 10-80% of vaccinated patients. 
However, in spite of the induction of peptide-specific CTLs, it has been reported that 
the anti-tumor effect was very limited. Recent studies have shown that the frequency of 
myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) is increased 
in HCC patients and the cells inhibit the function of T cells (33, 34). Therefore, 
controlling their function might be important to develop more effective vaccination for 
advanced HCC. 
In contrast, other recent studies using chondroitin-glucuronate C5-epimerase-derived 
peptides for other advanced cancers have shown the induction of cellular immune 
responses and clinical responses for certain patients (9, 11). In the analysis of the 
prognosis of patients with RFA and chondroitin-glucuronate C5-epimerase-derived 
peptide vaccination in the present study, the recurrence rate in the patients with an 
increase of the peptide-specific CTLs after vaccination was lower than that in the 
patients without immune response. Although further studies are necessary to evaluate 
the efficacy of chondroitin-glucuronate C5-epimerase-derived peptides for HCC, the 
results of our study suggest that chondroitin-glucuronate C5-epimerase is a potential 
candidate for a target of HCC immunotherapy.  
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In conclusion, chondroitin-glucuronate C5-epimerase is a potential candidate for a 
tumor antigen with immunogenicity, and peptides derived from the protein would be 
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a Histological degree of HCC; wel: well-differentiated, mod: moderately differentiated, por: poorly differentiated, ND: not determined. 







Table 2   Univariate analysis of the effect of variables on the T cell response against chondroitin-glucuronate C5-epimerase 
 Patients with positive 
T cell response 
Patients without positive 
T cell response 
p-value a 
 
No. of patients 15 22  
Age (years) b 64.6±9.8 68.7±5.9 NS 
Sex (M/F) 14/1 15/7 NS 
AFP (ng/ml) 3569.7±13070.0 580.7±2394.2 NS 
Diff. degree of HCC  
































TNM stage (I/II-IV) 4/11 8/14 NS 








Liver function (Child A/B/C) 11/4/0 13/7/2 NS 
Etiology (HCV/HBV/Others) 11/3/1 20/1/1 NS 
T cell response against to CMV pp65328 (+/-) 9/6 9/13 NS 
a NS: not significant. 
b Data are expressed as the mean ± SD. 







Table 3  Patient characteristics 
Patient Peptide  
Dose (mg)














A1 0.03 73 F HCV I 26 12 A F4A2 RFA - Pa(1) 
A2 0.03 78 F HCV I 45 10 B F4A2 RFA - P(1) 
A3 0.03 59 M NBNC II 30 10 A ND RFA - None 
B1 0.3 79 M HCV I 40 61 A F3A1 RFA - R(1), S(1) 
B2 0.3 72 M NBNC II 24 66 A ND RFA - R(1), S(1), P(1), H(1) 
B3 0.3 78 M HCV II 45 10 A F3A2 RFA - P(1) 
C1 3.0 67 M HCV I 111 49 A F3A1 RFA + P(1), S(1) 
C2 3.0 73 M NBNC I 30 5 A ND RFA - None 
C3 3.0 78 F HCV I 23 24 A F4A2 RFA + P(1) 
C4 3.0 75 M HBV I 21 15 A F3A1 RFA + R(1), P(1) 
C5 3.0 49 M HBV I 18 14 A F4A1 RFA + None 
C6 3.0 69 F HBV II 42 84 A F4A2 RFA - Pa(1) 






Figure 1:  Expression of chondroitin-glucuronate C5-epimerase. (A) 
immunofluorescence analysis for the expression of chondroitin-glucuronate 
C5-epimerase in hepatoma cell lines. Original magnification, X400. (B) 
Immunohistochemical analysis for the expression of chondroitin-glucuronate 
C5-epimerase and AFP in sequential non-cancerous and HCC tissue sections. Original 
magnification, X200 (left) and X400 (right). (C) Analysis of chondroitin-glucuronate 
C5-epimerase expression levels among the three groups (HCC; tumor tissue in HCC 
patients, Non-tumor; non-tumor tissue in HCC patients, Control; liver tissue in disease 
control groups). Closed and open circles show the level of chondroitin-glucuronate 
C5-epimerase expression in the patients with liver cirrhosis and chronic hepatitis, 
respectively. (D) The expression of chondroitin-glucuronate C5-epimerase was also 
compared with AFP expression in HCC tissues.  
 
Figure 2:  Immune responses of chondroitin-glucuronate C5-epimerase-specific T 
cells. (A) IFN- ELISPOT assay of PBMCs to chondroitin-glucuronate 
C5-epimerase-derived peptides (peptides 1, 2 and 3: solid bars) or control peptides 
(peptides HIVenv584 and CMVpp65328: open and grey bars, respectively) in normal 
donors and disease control groups. “N” denotes normal donors. “C” denotes the patients 
with chronic hepatitis. “L” denotes the patients with liver cirrhosis. % shows the ratio of 
the patients who showed positive responses. *denotes more than 30 specific spots. (B) 




Figure 3:  Characteristics of chondroitin-glucuronate C5-epimerase-specific CTLs. 
(A) IFN- ELISPOT assay of PBMCs and TILs to one of the chondroitin-glucuronate 
C5-epimerase-derived peptide (peptide 3) in 7 HCC patients. Open and solid bars show 
the frequency of chondroitin-glucuronate C5-epimerase-specific T cells in PBMCs and 
TILs, respectively. *denotes 114 specific spots. **denotes 42 specific spots. (B) 
Representative results of the CTL assay. The closed and open circles show the 
cytotoxicity against C1R-A*2402 cells pulsed with and without a peptide, respectively. 
(C) CTL assays (E/T ratio of 50:1) were performed in 18 HCC patients. Solid bars show 
the result for one patient. The results are shown as specific cytotoxic activity, which was 
calculated as follows: (cytotoxic activity in the presence of peptide) - (cytotoxic activity 
in the absence of peptide) and considered positive when higher than 10%. (D) 
Cytotoxicity of chondroitin-glucuronate C5-epimerase-specific T-cell lines derived with 
peptides was also measured against hepatoma cell lines. The cytotoxicity was 
considered positive when it was higher than that against K562 which shows 
non-specific lysis (E/T ratio of 50:1).  
 
Figure 4:  IFN- ELISPOT assays of PBMCs to chondroitin-glucuronate 
C5-epimerase-derived peptide (peptide 3) or control peptides (peptides HIVenv584 and 
CMVpp65328) in HCC patients with RFA. (A) The assays were performed in the patients 
with peptide 3 vaccination. White and black bars show the T cell responses before and 
after vaccination, respectively. (B) The assays were also performed in the patients 
without vaccination. White and black bars show the T cell responses before and after 
RFA, respectively. *denotes more than 50 specific spots. 
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a Histological degree of HCC; wel: well-differentiated, mod: moderately differentiated, por: poorly differentiated, ND: not determined. 
b Tumor size was divided into either ‘small’ (≦2 cm) or ‘large’ (＞2 cm).  
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Table 2   Univariate analysis of the effect of variables on the T cell response against chondroitin-glucuronate C5-epimerase 
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T cell response 
Patients without positive 
T cell response 
p-value a 
 
No. of patients 15 22  
Age (years) b 64.6±9.8 68.7±5.9 NS 
Sex (M/F) 14/1 15/7 NS 
AFP (ng/ml) 3569.7±13070.0 580.7±2394.2 NS 
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TNM stage (I/II-IV) 4/11 8/14 NS 








Liver function (Child A/B/C) 11/4/0 13/7/2 NS 
Etiology (HCV/HBV/Others) 11/3/1 20/1/1 NS 
T cell response against to CMV pp65328 (+/-) 9/6 9/13 NS 
a NS: not significant. 
b Data are expressed as the mean ± SD. 
c ND: not determined. 
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A1 0.03 73 F HCV I 26 12 A F4A2 RFA - Pa(1) 
A2 0.03 78 F HCV I 45 10 B F4A2 RFA - P(1) 
A3 0.03 59 M NBNC II 30 10 A ND RFA - None 
B1 0.3 79 M HCV I 40 61 A F3A1 RFA - R(1), S(1) 
B2 0.3 72 M NBNC II 24 66 A ND RFA - R(1), S(1), P(1), H(1) 
B3 0.3 78 M HCV II 45 10 A F3A2 RFA - P(1) 
C1 3.0 67 M HCV I 111 49 A F3A1 RFA + P(1), S(1) 
C2 3.0 73 M NBNC I 30 5 A ND RFA - None 
C3 3.0 78 F HCV I 23 24 A F4A2 RFA + P(1) 
C4 3.0 75 M HBV I 21 15 A F3A1 RFA + R(1), P(1) 
C5 3.0 49 M HBV I 18 14 A F4A1 RFA + None 
C6 3.0 69 F HBV II 42 84 A F4A2 RFA - Pa(1) 
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Peptide 1; 0/11(0.0%) 
Peptide 3; 0/11(0.0%) 













N1 N2 N3 N4 N5 N6 N7 N8 N9 N10 N11 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 L1 L2 L3 L4 L5 L6 L7 L8 L9 L10 C12 L11 
N1 N2 N3 N4 N5 N6 N7 N8 N9 N10 N11 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 L1 L2 L3 L4 L5 L6 L7 L8 L9 L10 C12 L11 
N1 N2 N3 N4 N5 N6 N7 N8 N9 N10 N11 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 L1 L2 L3 L4 L5 L6 L7 L8 L9 L10 C12 L11 
Peptide 1; 1/23(4.3%) 
Peptide 3; 1/23 (4.3%) 
Peptide 2; 1/23(4.3%) 
HIV env584; 0/11(0.0%) 









N1 N2 N3 N4 N5 N6 N7 N8 N9 N10 N11 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 L1 L2 L3 L4 L5 L6 L7 L8 L9 L10 C12 L11 
N1 N2 N3 N4 N5 N6 N7 N8 N9 N10 N11 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 L1 L2 L3 L4 L5 L6 L7 L8 L9 L10 C12 L11 
HIV env584; 0/23(0.0%) 
CMV pp65328; 8/23(34.8%) 
* * * * * * * * * 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 
Peptide 3; 10/37(27.0%) 
Peptide 1; 4/37(10.8%) 
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